City Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
City Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, City Therapeutics, Inc. Common Stock (CTY) has a cash flow conversion efficiency ratio of 0.069x as of June 2020. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($699.00 Million) by net assets ($10.12 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of City Therapeutics, Inc. Common Stock (2005–2025)
Cash flow conversion efficiency of City Therapeutics, Inc. Common Stock from 2005 to 2025. This chart illustrates how City Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View City Therapeutics, Inc. Common Stock stock quote for real-time trading data and today's change.
City Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
City Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
City Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of City Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see market value of City Therapeutics, Inc. Common Stock for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daily Journal Corp
NASDAQ:DJCO
|
0.032x |
|
Amerigo Resources Ltd.
TO:ARG
|
0.111x |
|
BrightView Holdings
NYSE:BV
|
0.033x |
|
Foshan Electrical and Lighting Co Ltd
SHE:000541
|
0.003x |
|
Ningbo Sunrise Elc Technology Co Ltd Class A
SHE:002937
|
0.017x |
|
SpartanNash Co
NASDAQ:SPTN
|
0.117x |
|
Hunan New Wellful Co Ltd
SHG:600975
|
0.064x |
|
ATEX Resources Inc.
V:ATX
|
-0.185x |
Annual Cash Flow Conversion Efficiency for City Therapeutics, Inc. Common Stock (2005–2025)
The table below shows the annual cash flow conversion efficiency of City Therapeutics, Inc. Common Stock from 2005 to 2025. Review CTY FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-84.66 Million | $-41.61 Million | 0.492x | -29.07% |
| 2024-12-31 | $-29.43 Million | $-20.39 Million | 0.693x | +110.41% |
| 2019-12-31 | $10.12 Billion | $3.33 Billion | 0.329x | -14.27% |
| 2018-12-31 | $9.87 Billion | $3.79 Billion | 0.384x | +47.31% |
| 2017-12-31 | $9.34 Billion | $2.44 Billion | 0.261x | -14.53% |
| 2016-12-31 | $8.69 Billion | $2.65 Billion | 0.305x | +4.89% |
| 2015-12-31 | $8.91 Billion | $2.59 Billion | 0.291x | -4.63% |
| 2014-12-31 | $9.18 Billion | $2.80 Billion | 0.305x | -72.96% |
| 2013-12-31 | $2.40 Billion | $2.71 Billion | 1.128x | +11.55% |
| 2012-12-31 | $2.74 Billion | $2.77 Billion | 1.011x | +7.75% |
| 2011-12-31 | $2.35 Billion | $2.20 Billion | 0.939x | +514.78% |
| 2010-12-31 | $-14.30 Billion | $3.23 Billion | -0.226x | +3.10% |
| 2009-12-31 | $-13.56 Billion | $3.17 Billion | -0.234x | +3.67% |
| 2008-12-31 | $-14.35 Billion | $3.48 Billion | -0.242x | -2.03% |
| 2007-12-31 | $-13.72 Billion | $3.26 Billion | -0.238x | -100.83% |
| 2006-12-31 | $110.00 Million | $3.13 Billion | 28.482x | +13497.96% |
| 2005-12-31 | $-16.07 Billion | $3.42 Billion | -0.213x | -- |
About City Therapeutics, Inc. Common Stock
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more